Actively Recruiting
Study on How Geriatric Evaluations Affect Treatment Guidance for Adults Over 50 with New AML Diagnosis
Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-08-07
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying acute myeloid leukemia AML in adults aged 50 and older to better understand physiologic age, which considers overall health rather than just calendar age. This observational study aims to evaluate how physiologic age relates to treatment outcomes like toxicity, early death, remission, and long-term survival for patients receiving intensive or non-intensive AML treatment. Participants will be assessed at the start of treatment and followed up at 14 days and one month after treatment begins. The study will measure physical function, depression, cognition, frailty, and patient-reported outcomes, along with albumin levels as a potential biomarker. These assessments will help create a screening tool to predict treatment risks and outcomes. During the study, patients will complete questionnaires and physical and cognitive evaluations at specified times. Researchers will monitor survival at one year, short-term mortality at 30 and 60 days, treatment toxicities, and remission rates. The study focuses on tracking changes in physical function over time to better understand the effects of AML treatment in older adults.
CONDITIONS
Brief Title
Assessment of Geriatric Evaluations Impact on New AML Guidance
Research Team
C
Colleen Redlinger
C
Catherine Lai, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
